Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond
Antibody Therapeutics · 01.04.2026 · 9 (2) · 201-213
DOI: 10.1093/abt/tbag015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 21.04.2026. Verfasst von Li-Min Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Hengrui Pharmaceuticals Co., Ltd, Jiangsu 222047, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Hengrui Pharmaceutical Co., Ltd, Shanghai Shengdi Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Background
Despite the success of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC), acquired resistance remains an unmet need. Although human epidermal growth factor receptor 3 (HER3) and c-Met upregulation are key mechanisms of this resistance, the rationale for simultaneously targeting both to overcome this challenge remains unexplored.
Methods
HER3 and c-Met expression were evaluated by immunohistochemistry in 270 clinical samples, including EGFR TKI-resistant NSCLC, lung adenocarcinoma (LUAD), gastric cancer, and colorectal cancer (CRC). The binding affinity of SDP0505 was measured by surface plasmon resonance and enzyme-linked immunosorbent assay, internalization was monitored using Incucyte, and in vitro cytotoxicity was assessed via CellTiter-Glo assay. The in vivo anti-tumor activities were investigated in cell-derived and patient-derived xenograft (PDX) models. Pharmacokinetics and repeated-dose toxicity were studied in cynomolgus monkeys.
Results
Immunohistochemical analyses revealed spatial colocalization of HER3 and c-Met in EGFR TKI-resistant NSCLC specimens. Furthermore, high co-expression was observed in 58% of EGFR-mutant LUAD and 95% of CRC cases. Consequently, SDP0505 was developed with optimal antigen-binding affinity and antibody format through comprehensive screening. In HER3/c-Met dual-positive cell lines, SDP0505 demonstrated enhanced cell binding and internalization over the in-house synthesized U3-1402 analog. Superior in vivo antitumor efficacy was also observed in multiple NSCLC and CRC models, including EGFR TKI-resistant PDX models. Moreover, SDP0505 exhibited favorable pharmacokinetic and safety profiles in cynomolgus monkeys.
Conclusions
SDP0505 represents a novel HER3 × c-Met ADC with superior internalization and anti-tumor activity in preclinical models, especially in EGFR TKI-resistant PDX models. These results supported the initiation of a Phase I clinical trial in China.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangsu Hengrui Pharmaceuticals Co., Ltd, Jiangsu 222047, China.
- Department of Tumor Biobank, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi 0…
ORCID-Profile: Li-Min Wang, Wei Zhang
Förderung
- Jiangsu Hengrui Pharmaceutical Co., Ltd
- Shanghai Shengdi Pharmaceutical Co., Ltd
Zitieren
APA
Wang, L. M., Yang, C., Chen, S., Sun, X., Tian, Y., Zhang, J., Gao, X., Li, D., Zhang, W., Hu, Y., Yuan, J., Xu, Q., Liu, X., Zhang, L., Yu, Q., & Liao, C. (2026). Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond. Antibody Therapeutics, 9(2), 201-213. https://doi.org/10.1093/abt/tbag015
Vancouver
Wang LM, Yang C, Chen S, Sun X, Tian Y, Zhang J, et al. Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond. Antibody Therapeutics. 2026;9(2):201-213. doi:10.1093/abt/tbag015
BibTeX
@article{Wang2026,
author = {Wang, Li-Min and Yang, Changyong and Chen, Simeng and Sun, Xing and Tian, Yunan and Zhang, Jieqiong and Gao, Xiaomeng and Li, Dan and Zhang, Wei and Hu, Yali and Yuan, Jimin and Xu, Qumiao and Liu, Xiyang and Zhang, Long and Yu, Qianqian and Liao, Cheng},
title = {Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond},
journal = {Antibody Therapeutics},
year = {2026},
volume = {9},
number = {2},
pages = {201--213},
doi = {10.1093/abt/tbag015}
}
EUVIMED